Podcasts about cervical cancer screening

Dr. Barbara Moscicki discusses the critical role of HPV in women's health, particularly its association with various cancers, including cervical cancer. She explains the dual nature of HPV as both a commensal organism and a pathogen, emphasizing the importance of understanding its oncogenic potential. The conversation also covers the significance of screening methods, such as Pap smears, in detecting precancerous changes and the complexities surrounding the treatment of different cervical intraepithelial neoplasia (CIN) stages. This conversation delves into the complexities of cancer screening methods, particularly focusing on cervical and anal cancer. Dr. Barbara Moscicki discusses the importance of understanding various screening guidelines, the role of HPV vaccination in preventing cancers, and the need for clear communication between clinicians and patients regarding these topics. The discussion highlights the evolving nature of cancer screening practices and the importance of patient education in navigating these changes.About Our Guest:Dr. Moscicki is a Pediatrician, Board Certified in Adolescent Medicine. She is the current Division Chief of Adolescent and Young Adult Medicine with clinical expertise in reproductive health care for menstrual irregularities, sexual health, and sexually transmitted diseases. Dr. Moscicki has expertise in HPV -related disease including diagnosis of cervical dysplasia and treatment. She also offers medical care for women with eating disorders.Resources & Links:This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features the PCORI research study here: https://pubmed.ncbi.nlm.nih.gov/33632649/ ‘Effect of 2 Interventions on Cervical Cancer Screening Guideline Adherence'Chapter Codes00:00 Introduction to HPV and Women's Health03:00 Understanding HPV's Role in Cancer06:01 The Dual Nature of HPV: Commensal vs Pathogenic08:57 Oncogenes and Their Impact on Cellular Regulation12:09 The Intersection of HPV and Screening Methods14:58 Cervical Cancer Screening and Pap Smears20:30 Understanding Cancer Screening Methods23:17 Guidelines for Cervical and Anal Cancer Screening31:02 The Importance of HPV Vaccination39:35 Key Messages for Clinicians and PatientsTakeaways- Dr. Moscicki specializes in adolescent and young adult medicine.- HPV is linked to multiple cancers beyond cervical cancer.- The understanding of HPV's role in cancer has evolved significantly.- E6 and E7 proteins from HPV disrupt normal cell regulation.- CIN3 is considered a true pre-cancer that requires treatment.- Liquid cytology has improved the accuracy of Pap smears.- CIN1 is often self-resolving and does not require treatment.- CIN2 presents a diagnostic dilemma due to variability in interpretation.- Women have options regarding the management of CIN2 lesions.Connect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrw YouTube: https://www.youtube.com/@mantacares Spotify: https://open.spotify.com/episode/3TR1lFLtf6em5YyKtlWy2L?si=6ma-9g_w Apple: https://podcasts.apple.com/us/podcast/navigating-cervical-cancer-screening-surger Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute.

A major cervical cancer screening unit at Helen Joseph Hospital in Johannesburg has shut down this week after losing crucial US funding. The closure threatens to worsen delays in early detection, risking lives in a country already battling one of the world's highest cervical cancer rates. Clinics across Gauteng are overwhelmed, and medical experts warn that without urgent donor support, many South African women may face late diagnoses and preventable deaths. Elvis Presslin spoke to Dr. Mark Faesen, a specialist gynaecologist working with the Clinical HIV Research Unit (CHRU)...

What is travel illness? Can I test for HPV at home? How many cases of measles are there? What are vector-borne diseases? How dangerous is bird flu to humans? Discussing over 1000 confirmed measles cases, H5N1 bird flu, healthy travel health tips for summer, a new at-home pap smear FDA approved test, and a JAMA study on prenatal cannabis use with AMA's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH. American Medical Association CXO Todd Unger hosts.

Dr. Shannon McLaughlin-David discusses the complexities of cervical cancer, HPV, and the role of gynecologic oncology. The dialogue explores the emotional and clinical challenges faced by both patients and clinicians, emphasizing the importance of effective communication and empathy in patient care. The discussion also highlights the various types of gynecologic cancers, surgical interventions, and the difficult decisions patients must make regarding their treatment options. This conversation delves into the complexities of patient autonomy, the emotional challenges faced by oncologists, and the systemic incentives within healthcare that can impact patient care. The discussion also covers the evolution of cervical cancer screening guidelines, the role of HPV in cervical cancer, and the importance of patient advocacy and education regarding vaccination.Resources & Links:This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features the PCORI research study here: https://www.google.com/url?q=https://pubmed.ncbi.nlm.nih.gov/33632649/&sa=D&source=editors&ust=1746483503903350&usg=AOvVaw0SNo_jk-rzoVp85P5E3s6F ‘Effect of 2 Interventions on Cervical Cancer Screening Guideline Adherence'Chapter Codes00:00 Introduction to Cervical Cancer and HPV02:49 The Journey to Gynecologic Oncology05:57 Understanding Gynecologic Cancers09:05 Surgical Interventions in Gynecologic Oncology11:59 The Complexity of Patient Decisions15:07 Patient-Clinician Communication Challenges17:45 The Role of Empathy in Oncology21:05 Navigating Hormonal Treatments and Patient Reactions27:30 Navigating Patient Autonomy and Medical Ethics29:47 The Emotional Toll of Oncology33:00 Understanding the Healthcare System's Incentives35:58 The Role of Patient Advocacy39:05 The Evolution of Cervical Cancer Screening Guidelines51:46 HPV and Its Impact on Cervical Cancer54:48 Current Screening Protocols and HPV VaccinationConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://www.youtube.com/@mantacares/videosSpotify: https://open.spotify.com/episode/0rSG16JUXGnRmOPfpJSplS?si=ayogPMUMT4eHJclXn6_5xA Apple: https://podcasts.apple.com/us/podcast/the-microbiomes-impact-on-colorectal-cancer/id1622669098?i=1000705538270 Tags & Keywords:cervical cancer, HPV, gynecologic oncology, patient communication, surgical interventions, women's health, cancer treatment, patient empathy, decision making, hormonal therapy, patient autonomy, medical ethics, oncology, healthcare system, patient advocacy, cervical cancer, HPV, screening guidelines, emotional toll, healthcare incentives#Storytelling #Identity #Representation #Authenticity #Podcast #Culture #CancerAwareness #MedicalPodcast #CancerSurvivor #Oncology #Healthcare #CancerSupport #PatientStories #CancerResearch #HealthPodcast #CancerCommunity #SurvivorStories #MentalHealth #Wellness #HealthcareInnovationDisclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute.

Halle McNamarra, second-year master of science student in public health at McGill University and Fiona Kavcic, second-year master of science student in public health at McGill University

Send us a textListen to this replay of "Cervical Cancer Awareness" from Season 2 with guest Dr. Sharon Sutherland from the Cleveland Clinic. Speaking of Women's Health Podcast host Holly Thacker, MD focuses her questions on raising awareness about cervical cancer and the importance of regular screenings to prevent it.January is Cervical Cancer Awareness month, so there's no better time to hear about how you can prevent cervical cancer with regular screenings.Fit, Healthy & Happy Podcast Welcome to the Fit, Healthy and Happy Podcast hosted by Josh and Kyle from Colossus...Listen on: Apple Podcasts SpotifySupport the show

AP correspondent Shelley Adler reports an influential health panel says women should have the option of taking their own test samples for cervical cancer screenings.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-400 Overview: The FDA recently approved primary human papillomavirus (HPV) self-collection for cervical cancer screening in a healthcare setting. Join us as we explore how to counsel patients on this less invasive method and find out what's on the horizon for at-home collection kits. Episode resource links: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160037 Journal of Clinical Virology, 2020-06-01, Volume 127, Article 104375, Copyright © 2020 Elsevier B.V.  JAMA. 2023;330(20):1971-1981. doi:10.1001/jama.2023.21471 Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-400 Overview: The FDA recently approved primary human papillomavirus (HPV) self-collection for cervical cancer screening in a healthcare setting. Join us as we explore how to counsel patients on this less invasive method and find out what's on the horizon for at-home collection kits. Episode resource links: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160037 Journal of Clinical Virology, 2020-06-01, Volume 127, Article 104375, Copyright © 2020 Elsevier B.V.  JAMA. 2023;330(20):1971-1981. doi:10.1001/jama.2023.21471 Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Dr Anita Lim joins Elena Bellafante, Deputy Editor for eClinicalMedicine, to talk about her recent publication of the YouScreen study, a pragmatic implementation feasibility trial that assessed the impact of offering self-sampling to non-attenders within the English cervical cancer screening programme.Read the full article:https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00251-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_eclinmContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

DB sits down with her amazing mom, Dr. Rebecca Levy-Gantt, to dive into the latest updates on pap smear options and new guidelines for managing pain during IUD insertions! They discuss the benefits of self-collection kits for cervical cancer screening, changes in pap smear recommendations, and uncover what these updates mean for better, more comfortable care. Plus... learn how IUD insertion is becoming a lot less painful! Dr. Rebecca Levy-Gantt is an ObGyn in private practice in Napa, California who focuses on menopause but at the current time, takes care of girls and women at all ages, 14-94. She is on LinkedIn, and her practice website is Premierobgynnapa.com. Find her books here. ——   Do you have a silly sex story to share, need some advice, or have thoughts on the episode you just heard? Send us a voicemail for a chance to be featured on the podcast!  —— Follow Sex Ed with DB on: Instagram: @sexedwithdbpodcast TikTok: @sexedwithdbTwitter : @sexedwithdbThreads: @sexedwithdbpodcast YouTube: Sex Ed with DB Rep your favorite sex ed podcast with our brand new merch! Sign up for our newsletter with BTS content and exclusive giveaways here. Are you a sexual health professional? Check out DB's workshop: Building A Profitable Online Sexual Health Brand. Want to get in touch with Sex Ed with DB? Email us at sexedwithdb@gmail.com. —— Sex Ed with DB, Season 10 is Sponsored by: Lion's Den, Uberlube, and Magic Wand. Get discounts on all of DB's favorite things here! —— About Sex Ed with DB: Sex Ed with DB is a feminist podcast bringing you all the sex ed you never got through unique and entertaining storytelling, centering LGBTQ+ and BIPOC experts. We discuss topics such as birth control, pleasure, LGBTQ+ health and rights, abortion, consent, BDSM, sex and disability, HIV, sex in the media, and more. —— Sex Ed with DB, Season 10 Team: Creator, Host, Executive Producer: Danielle Bezalel (DB) Producer: Sadie Lidji Communications Lead: Cathren Cohen Marketing Coordinator: Mitch Coburn Social Media Coordinator: Emm-Kirsty Fraser

On this episode, we have Mark Owen from Viospex and Dr. Jean Bouquet from the Boquet Speculum discussing a new speculum for screening women in pelvic health physical therapy. With a rise in cervical cancer due to missed postpartum follow-ups, the $7.50 cervical cancer cure kit is highlighted. Dr. Jean Boquet shares the inspiration behind the speculum design from his experience as a family practice physician. Tune in to learn more about this innovative approach to women's health screening.Timestamps(01:08) The Bouquet Speculum is a cost-effective solution for cervical cancer screening, priced at $7.50 per woman, making it accessible for underserved nations.(15:32) The Bouquet Speculum provides a clear view of the cervix, making it easier for healthcare providers to conduct cervical examinations, especially for novices.(25:20) The rise in cervical cancer cases post-COVID highlights the importance of regular screenings and the need for improved access to cervical cancer screening tools like the Bouquet Speculum.(34:27) The strategy behind the Bouquet Speculum involves targeting Western markets initially to create demand and drive down prices, ultimately making it more accessible globally.(55:30) The collaborative relationship between Jean and Mark leverages Jean's technical expertise and Mark's commercial acumen to strategically introduce the Bouquet Speculum to different markets, starting with Europe and the US.Host BioThis podcast is hosted by Sheree Dibiase, PT ICLM. She is a nationally recognized women's health physical therapist who owns seven private clinics — one of the biggest networks in the US. She has spent 30+ years practicing in the oncology, pelvic floor, and prenatal postpartum healthcare spaces. She was also a professor for seven years a Loma Linda University where she taught kinesiology. Brought to you by...https://lakecitypt.com/ - Women's health physical therapy. https://pelvicfloorpro.com/ - Pelvic floor physical therapy from home. KeywordsFemtech, Women's Health, Pelvic Floor, Breast Cancer, Prenatal & postpartum

In this Healthed lecture, Dr Nomvuyo Mothobi will bring us up to date on the current state of play of cervical screening in Australia.See omnystudio.com/listener for privacy information.

CME credits: 0.25 Valid until: 29-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consensus-recommendations-for-use-of-p16ki67-dual-staining-cytology-in-the-management-of-individuals-testing-positive-for-hpv/14675/ More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.=

            For medical writing assistance, please visit nascentmc.com learnAMAstyle.com for the AI in Medical Writing and Editing: Blueprint for Success in a Changing World course to assist with implementing AI in medical writing.  •    Imdelltra for EC-SCLC: The FDA granted accelerated approval for tarlatamab-dlle (Imdelltra) for adults with extensive-stage small cell lung cancer (ES-SCLC) who progressed after platinum-based chemotherapy. Small cell lung cancer, accounting for 10-15% of all lung cancers, is aggressive with a median survival of 12 months post-therapy. Imdelltra, a first-in-class BiTE therapy targeting DLL3, showed a 40% objective response rate and a median overall survival of 14.3 months in the phase 2 DeLLphi-301 trial. •    Breyanzi for R/R LL: The FDA granted accelerated approval for lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory follicular lymphoma after two or more systemic therapies. This CAR T-cell therapy, already approved for other B-cell malignancies, genetically modifies T cells to target tumor antigens. In the TRANSCEND FL trial, Breyanzi achieved a 95.7% overall response rate in 94 patients, with the median response duration not reached after 16.8 months. •    SNB-101 for SCLC: The FDA granted fast-track designation to SNB-101 for small cell lung cancer (SCLC). SNB-101, a polymer nanoparticle formulation of the antineoplastic agent SN-38, enhances lung-specific delivery and efficacy. Early data indicates improved tolerability and efficacy, with global phase 2 trials planned for various solid tumors including colon and gastric cancers, led by SN BioScience. •    Upstaza for AADC Deficiency: The FDA accepted the Biologics License Application for eladocagene exuparvovec (Upstaza), a gene therapy for aromatic L–amino acid decarboxylase (AADC) deficiency, with a Priority Review and a target date of November 13, 2024. Upstaza delivers the human DDC gene to the putamen, increasing AADC enzyme levels to restore dopamine production, showing significant neurological improvements in clinical trials. Approval was granted to PTC Therapeutics, Inc. •    Altuviiio for Hemophilia A Label Update: The FDA approved an updated label for Altuviiio (antihemophilic factor, recombinant), including phase 3 XTEND-Kids trial results. This high-sustained factor VIII replacement therapy, initially approved in 2023, offers prolonged bleed protection for pediatric patients under 12 years with hemophilia A. The updated label confirms Altuviiio's safety and effectiveness for both routine and on-demand treatment. •    Self-Collected Sample for Cervical Cancer Screening: The FDA approved the BD Onclarity™ HPV Assay for self-collected vaginal specimens for HPV testing when traditional cervical samples are not available. This assay, identifying six HPV strains, enhances screening access, especially for underserved populations with higher cervical cancer rates. Approval was granted to Becton Dickinson. •    Clinolipid Parenteral Nutrition: The FDA approved Clinolipid (Lipid Injectable Emulsion) for pediatric patients, including preterm and term neonates. Clinolipid, a mixed oil lipid emulsion providing essential fatty acids and calories, has been available for adults since 2019 and is now approved for all ages. Approval was granted to Baxter International Inc.

 In this episode, The Hindu speaks to doctors to understand the link between HPV and cervical cancer, and why screening rates are so low in India, compared to other countries. They say one major reason why women don't get screened often, or at all, is because while women are predominantly viewed as caregivers, they often do not prioritise their own needs. While on the one hand, they want more women to get screened, when it comes to vaccination against HPV, they want it to be gender-neutral. They also discuss the need for greater awareness and a structured state intervention programme to boost screening and vaccination. Guest: Dr Aravind Krishnamurthy: Head of Surgical Oncology at the Cancer Institute, Chennai Dr Sunita Tandulwadkar: President-Elect of the Federation of Obstetric and Gynaecological Societies of India (FOGSI)  Credit to Sonikka Loganathan and Rebecca Rose Varghese

In this episode, Cara and Missi discuss recent updates to cervical cancer screening and management of results. They give a brief history of cervical cancer screening, incidence and mortality for cervical cancer in the US, and recommendations for the frequency of screening. Then, they provide an update to screening abnormalities and how to individualize follow-up management for patients.  #cervicalcancer #screening #cancer #gynecology #womenshealth #cytology #midwivesmakeadifference #vaccinessavelives #HPV

Women who were due for cervical cancer screening and were mailed a self-sampling kit at home along with educational materials were more likely to complete screening than those offered educational materials alone and then had to request a kit, a … Would you be more likely to have cervical cancer screening if a kit was mailed to you at home? Elizabeth Tracey reports Read More »

Host: Darryl S. Chutka, M.D., @ChutkaMD Guest: Evelyn A. Reynolds, M.D. January is Cervical Cancer Awareness Month | Cervical cancer is the fourth most common malignancy in women worldwide, although the number of new cases in the U.S. has been declining. The vast majority of cervical cancers are caused by infection with the Human Papilloma Virus. Due to a combination of HPV immunization and early detection with cervical cancer screening, advanced cases are becoming much less common and when detected early, cervical cancer is one of the more treatable malignancies. Although cervical cancer screening is relatively easy to perform, the guidelines for performing the test have become more complicated. In this podcast, we'll discuss cervical cancer screening with my guest Evelyn A. Reynolds, M.D., from the Department of Obstetrics and Gynecology at the Mayo Clinic. I'll be asking her when to start screening, how often patients should be screened, when we can stop screening and more. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

The wild winter weather continues to impact the province. BC Ferries had to cancel at least one sailing due to high winds, and numerous outages on Vancouver Island, the Lower Mainland and the Sunshine Coast due to the storm had B.C. Hydro crews busy. But the skiers were happy with the new snow according to our guest Tuppy Hoehn, head coaching team, Caledonia Nordic Ski Club. In our second segment, our guest Peter Milobar, B.C. United MLA for Kamloops-North Thompson, outlines his concern with cancer care in B.C. And we explore the announcement of a new cervical cancer screening process in B.C. with family doctor Dr. Maryam Zeineddin, Ambleside Medical Care.

Cervical cancer is one of the most treatable types of cancer, if it's caught early enough. It's also one of the only types of cancer that can be prevented through a vaccine. Our healthcare columnist Mary Jane Hampton explains in this week's health hack.

Cervical cancer screening is effective when done as recommended. JAMA Deputy Editor Linda Brubaker, MD, speaks with Rachel L. Winer, PhD, MPH, of the University of Washington, about a recent trial in JAMA that compared cervical cancer screening strategies, including direct-mail and opt-in approaches for human papillomavirus (HPV) self-sampling. Related Content: Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits

Editor's Summary by Mary McGrae McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the November 28, 2023, issue. Related Content: Audio Highlights

CME credits: 1.50 Valid until: 21-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/kol-knockouttm-cancer-pain-management-edition/15994/ This enduring program of the live-virtual symposium will focus on the challenges of managing cancer pain using the Evolve KOL Knockout™ case-based format. The key opinion leaders (KOLs) will be challenged by the host/moderator to diagnose and manage patient scenarios with varying levels of difficulty. Learners will vote on the winner of each case presentation round and the moderator will declare a match winner at the conclusion. There will be learning, laughter, and only one KOL left standing! =

Visit my Patreon page for a detailed summary of these guidelines with links, graphics, and more!#DoNoHarmTakeNoShitJoin the waitlist for Clear+Free: Your Holistic Solution to Persistent HPVEnroll in the Born Free MethodFind me on InstagramMidwife Collaborator Program(Looking for my other podcast? Go HERE for The Holistic OBGYN)**Medical Disclaimer: The Holistic OBGYN Podcast is an educational program. No information conveyed through this podcast should be construed as medical advice. These conversations are available to the public for educational and entertainment purposes only.

Diagnoses of serious abnormalities in cervical screening have fallen by almost 60 per cent. That's according to a new study published in the Irish Journal of Medical Science on the effectiveness of the HPV vaccine. Kieran was joined by Dr Lucy Jessop HSE Immunisation Lead and Consultant in Public Health Medicine at the National Immunisation Office...

Cervical screening campaign encourages Pasifika women to self-test.

CME credits: 0.50 Valid until: 19-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/closing-the-gap-personalized-approaches-to-cervical-cancer-screening-and-treatment/15666/ Despite effective screening methods for cervical cancer, many women do not have access or are not screened in a timely manner which results in delayed diagnosis and higher rates of advanced disease with lower survival rates. In recent years, immunotherapy has emerged as a new frontline treatment option that improves outcomes in women with PD-L1 positive advanced cervical cancer. In this activity you will learn about one patient's journey with advanced cervical cancer, including her symptoms, the importance of biomarker testing, and her experience with immunotherapy. =

On this episode of a Cancer Conversation, we have a guest host! Lindsey moved from behind the cameras to the front of them to fill in for Chris and to discuss cervical cancer and screening options with Dr. Higgins! To learn more, visit: https://news.augustahealth.org/2023/0...

It's not only the winter weather that has the power to make you gloomy but the heat too. Valens Clinic discusses SAD or Seasonal Affective DisorderDr Ibrahim Abd Elrahman from King's College Hospital Dubai advises why women need to get regular cervical checks.Tutoring and getting the kids ready for going back to school is what Cassie Culverhouse from Palm Education discussesLessening youth unemployment is one of the goals of Abdullah Al Ghurair FoundationAnd the best meteor shower of the year is happening this weekend- Hasan Al Hariri from the Dubai Astronomy Group tells us where and how to best view this celestial event.See omnystudio.com/listener for privacy information.

Editor's Summary by Anne Rentoumis Cappola, MD, ScM, Associate Editor of JAMA, the Journal of the American Medical Association, for the August 8, 2023, issue.

Dr. Togas Tulandi, professor and chair of obstetrics and gynecology at McGill University Learn more about your ad choices. Visit megaphone.fm/adchoices

CME credits: 0.25 Valid until: 12-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-of-the-patient-in-midlife-weighing-potential-changes-in-asccp-guidelines/14674/ Effective triage tests are needed to lessen diagnostic uncertainty when assessing cervical cancer risk and selecting which patients will move on to colposcopy. An FDA-approved dual-staining cytology test is available that can help in decision-making for a wide range of patients. Join Drs. Warner Huh and Sarah Dilley as they address current 2019 ASCCP guidelines and anticipate potential updates to ASCCP's guidance in 2023.=

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche.All other product names and trademarks are the property of their respective owners. 02/23

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche.All other product names and trademarks are the property of their respective owners. 02/23

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche.All other product names and trademarks are the property of their respective owners. 02/23

Did you know that regular cervical cancer screenings can detect abnormal cells early, before they become cancer? Listen to Obstetrician and Gynecologist (OB/GYN) Jenny Pennycook, MD, discuss the importance of cervical cancer screenings for women.

On this episode of Inside Health Care, we hear from a digital scientist and researcher eagerly finding tech solutions to promote immediate change in health care.Jennifer C. Goldsack is founder and CEO of the Digital Medicine Society (DiMe), a 501(c)(3) non-profit organization dedicated to advancing digital medicine to optimize human health. Jen earned her master's degree in chemistry from the University of Oxford, England, her masters in the history and sociology of medicine from the University of Pennsylvania, and her MBA from the George Washington University. And she's the first Olympian to appear on the podcast, a rower for the U.S. at the 2008 Beijing Olympics. Jen will also be a speaker at NCQA's 2023 Quality Talks event.Later, in our Fast Facts segment, we observe Endometriosis Awareness Month, with important information from Endometriosis.org. We also discuss NCQA's Cervical Cancer Screening measure, or CCS, part of our HEDIS measures. CCS contains a number of assessments for women who had cervical cytology and/or high-risk HPV testing within the last few years.

CME credits: 0.25 Valid until: 07-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/cervical-cancer-screening-the-case-of-the-young-patient/14673/ Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? Leading experts, Drs. Leigh Cantrell and Warner Huh, review the benefits of primary screening as they explore shifts in current guidelines. Find out how you can improve outcomes for patients, not only through appropriate primary HPV testing in lieu of cytology as the screening modality, but also by reinforcing how a “negative” HPV test actually sends a powerful “positive” message. As a bonus, you might just change a young patient's life.=

Despite increased screening and HPV vaccines, cervical cancer remains the fourth-leading cause of cancer death among women worldwide. Screening guidelines are constantly scrutinized and reassessed. The most current U.S. Preventative Services Task Force (USPSTF) guidelines recommend screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk HPV testing, or every 5 years with high-risk HPV testing with cytology. To get the full picture on how gynecologists and oncologists today are navigating screening guidelines and new treatment options with their patients, Oncology Times interviewed Deanna Gerber, MD, an obstetrics and gynecology specialist at NYU Langone Health’s Perlmutter Cancer Center. Gerber treats women who have cancer of the reproductive tract and who have been diagnosed with a genetic mutation that increases their risk of gynecologic cancer. She offers preventive treatments and risk-reducing surgery as a routine part of her care approach. She discussed how oncologists can approach conversations around screening and address the issue of screening overuse and underuse.

Fourteen thousand women are diagnosed with cervical cancer each year despite the effectiveness of vaccination and screening at preventing the disease. Dr. Huh is joined by Haller Smith, MD, a specialist in gynecologic oncology, to discuss strides in screening that have already reduced cervical cancer by 75%, as well as the obstacles to improving prevention even more. Dr. Smith discusses the latest screening and prevention guidelines, which emphasize the effectiveness of HPV vaccines and testing. The doctors discuss the promise of HPV self-sampling as one screening solution for those with limited access to health care.

Host: Jennifer Caudle, DO Guest: Diane M. Harper, MD, MPH, MS There are several testing methods available for cervical cancer screening, such as co-testing and primary HPV testing. So what are some of the most prominent benefits and limitations of these and other testing approaches? Joining Dr. Jennifer Caudle to break down the latest advancements in cervical cancer screening is Dr. Diane Harper, a Professor in the Departments of Family Medicine and Obstetrics and Gynecology at the University of Michigan.

CME credits: 0.50 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/transforming-cervical-cancer-screening-and-management-new-guidelines-new-tests-a-case-based-discussion/14676/ Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.

A cervical cancer screening study will give its participants the option to test at home.  The study will look at the impacts of the Human Papillomavirus (HPV) test, which will be Aotearoa's main screening method for cervical cancer from next year.  About 3,000 participants will be able to choose whether to have their test at their doctor's surgery or do it themselves from home.  University of Otago, Christchurch, associate professor Peter Sykes spoke to Māni Dunlop.   

The importance of cervical cancer screening in the U.S.Why is cervical screening so important in the U.S. and globally? And how has the pandemic affected that screening? Today's episode features Chris Beddard, VP of US Marketing at BD. She joins the podcast today to discuss a product she and her team have been working on to improve the lives of women. Chris is passionate about bringing awareness about health options to women around the world. Listen to the episode to hear what Chris has to say about why the test she's been working on is special, what kinds of challenges a team faces when developing these tests, and why cervical cancer screening is so important. Some of the highlights of today's episode include:What BD is doing and how Chris is working with itHow to go about choosing specific treatments to targetWhat makes the current test specialCervical screening focus on women in AfricaChallenges in developing testsWhy cervical cancer screening matters so muchThe ongoing impact of the pandemic on testingAdvice for medical health professionals in the process of long-term developmentMemorable quotes from Chris Beddard:“Extended genotyping provides different information, information that's critical to a clinician to basically manage a woman's risk for developing cervical cancer or precancer.”“In order to get all three testing paradigms approved through the FDA, there was an extensive clinical trials that did take place, again spanning many years.”“HPV is the most common sexually transmitted infection in the United States.”“We're seeing women returning to testing; we're seeing –again –our view of healthcare changing based on the pandemic.”Links:Chris BeddardBDEtienne Nichols LinkedInetienne.nichols@greenlight.guruMedTech Excellence CommunityGreenlight Guru AcademyGreenlight Guru

In conjunction with Merdeka and Malaysia Day 2022, Health & Living features healthcare heroes - individuals and organisations on a mission to make healthcare accessible to marginalised communities across Malaysia. Non-profit organisation ROSE Foundation was set up in 2019 with the ambitious goal of making Malaysia one of the first countries in the region to be free of cervical cancer, through its Program ROSE (Removing Obstacles to cervical ScrEening). Having traversed cross-country to screen more than 20,000 women, Prof Dato' Dr Adeeba Kamarulzaman and Prof Dr Woo Yin Ling, Chair and Founder of ROSE Foundation, respectively, join us to share how the program has made cervical cancer screening accessible to women in rural, remote and indigenous communities.Image credit: Facebook / Program ROSE

SURVEY LINK: https://bit.ly/feedback_UltraSounds SUMMARY: Brittany and Jourdan discuss five clinical vignettes regarding cervical cancer screening with Dr. Elizabeth Campbell, MD. TIMESTAMPS: 00:30: Intro 00:43: Dr. Campbell Bio 01:09: Case 1: 27 year old with LSIL 03:52: Case 2: 34 year old with a history of atypical squamous cells of unknown significance 06:14: Case 3: 44 year old presenting with post-coital vaginal bleeding 09:12: Case 4: 67 year old with considerations for screening 12:21: Case 5: 16 year old unvaccinated against HPV 16:23: Wrap-up LINKS: Recommendation: Cervical Cancer: Screening. US Preventive Services Taskforce, 21 Aug. 2018. HPV Vaccination. American College of Obstetricians & Gynecologists Abnormal Cervical Cancer Screening Test Results. American College of Obstetricians & Gynecologists American College of Obstetricians and Gynecologists. Updated guidelines for management of cervical cancer screening abnormalities. Practice Advisory. Washington, DC: American College of Obstetricians and Gynecologists; 2021. Fontham, Elizabeth T., et al. “Cervical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update from the American Cancer Society.” Khan, Michelle J. et al. “ASCCP Colposcopy Standards: Role of Colposcopy, Benefits, Potential Harms, and Terminology for Colposcopic Practice.” Cervical Intraepithelial Neoplasia Management, Up to Date Colposcopy, Up to Date Cervical Cancer Screening Management, Up to Date HPV Vaccination Recommendations. Centers for Disease Control and Prevention TRANSCRIPT: https://bit.ly/ultrasounds_CervicalCancerScreen DISCLOSURES/DISCLAIMERS: The OBGYN Delivered student team has no relevant financial disclosures. The Ultrasounds podcast is for educational and informational purposes only and should not be considered medical advice. Please do not use any of the information presented to treat, diagnose, or prevent real life medical concerns. The statements made on this podcast are solely those of the OB/GYN Delivered hosts and guests and do not reflect the views of any specific institution.

Guest:  Professor Lynette Denny is head of the Department of Obstetrics and Gynaecology at the University of Cape Town (UCT) with a lifelong career in cervical cancer research and she joins us now.See omnystudio.com/listener for privacy information.

Host: Darryl S. Chutka, M.D. (@ChutkaMD) Guest: Kathy L. MacLaughlin, M.D. Worldwide, cervical cancer is a very common malignancy for women, although the number of new cases in the U.S. has been declining. The overwhelming majority of cases are caused by infection with the human papilloma virus and due to a combination of HPV immunization and early detection with cervical cancer screening, advanced cervical cancer should be preventable. If it does occur, cervical cancer is one of the more treatable malignancies when detected early. If you perform cervical cancer screening for your patients, you know the guidelines have become a bit more complicated than in the past. To help us sort out who is a candidate for cervical cancer screening, when screening should start, how often it should be performed and when it can stop, we have as our guest for this podcast, Kathy L. MacLaughlin, M.D., a family physician in the Department of Family Medicine at the Mayo Clinic. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd

In this episode, we speak with Dr. Jane Montealegre, the Deputy Director of the Office of Outreach and Health Disparities at Baylor College of Medicine. We learn about Dr. Montealegre's work on cervical cancer screening and prevention, including her ongoing research on mailed, self-collected HPV testing kits. In this podcast, we explore the future of cancer screening and prevention, and how to better reach underserved groups.